Methods: Forty-three patients with refractory inflammatory bowel disease, who received infliximab treatment in our hospital between 2008 and 2013, were enrolled in the study. Adverse drug reaction (ADR) information was collected for time of onset, severity and outcome. Results: Of the 43 patients who received scheduled infusion of infliximab, 34 (79%) achieved clinical remission within 8 weeks after initiating infliximab treatment. Only 4 patients suffered ADRs, including Palbociclib research buy flushing (n = 4), dizziness (n = 3), headache (n = 3), nausea (n = 2), chest discomfort (n = 1), fever

(n = 1). No patient was severe and required active physician intervention. Slow infusion rate to 10 mL/h and pretreated with diphenhydramine and acetaminophen before infusion can prevent ADRs. Conclusion: Infliximab infusions are safe and effective in refractory inflammatory bowel Daporinad datasheet disease. Sever ADRs were rare. Nurses were significant

in prevention and treatment of ADRs. Key Word(s): 1. Inflammatory bowel disease; 2. adverse events; 3. infliximab Presenting Author: KWAK MIN SEOB Additional Authors: KYUNG JO KIM, SUK KYUN YANG, SEUNG JAE MYUNG, JEONG SIK BYEON, YE BYONG DUK, YANG DONG-HOON, SANG HYOUNG PARK, HYO JEONG LEE, HO SOO LEE, MIN KEUN CHO Corresponding Author: KWAK MIN SEOB Affiliations: University of Ulsan College of Medicine, University of Ulsan College of Medicine, University of Ulsan College of Medicine, University of Ulsan College of Medicine, University of Ulsan College of Medicine, University of Ulsan College of Medicine, University of Ulsan College of Medicine, University of Ulsan College

of Medicine, University of Ulsan College of Medicine, University of Ulsan College of Medicine Objective: Crohn’s disease (CD) leads mostly to irreversible intestinal damage through continuing relapses and remissions. Despite the debate of efficacy, 5-ASA remain the mainstay in the management of mild CD, only for the reason that these are the most widely investigated agents available so far. So, we investigated the natural CHIR-99021 supplier course of mild CD to assess whether current treatment strategies are indeed true for the patients with mild disease activity. Methods: A total of 104 patients with mild CD were enrolled between January 2008 and May 2014. This inception cohort study included 53 patients who were newly diagnosed with CD and who started treatment at Asan medical center, Seoul, Korea. The remaining 51 patients were refered to our center during same period. The long-term outcomes of them were investigated. Results: The median follow-up length for patients was 28.2 months (Range, 64.2 or IQR, 26.7). The clinical remission rates at 1, 3, and 5 years were noted in 12.6%, 63.5% and 95.9% of the patients, respectively. In the patients, 5.1% relapsed at 1 year. This percentage increased to 27.3% at 3 years and to 65.1% at 5 years.